Melatonin and Cardioprotection in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

cardioprotection and ischemia-reperfusion injury human melatonin meta-analysis randomized controlled (clinical) trial

Journal

Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388

Informations de publication

Date de publication:
2021
Historique:
received: 15 12 2020
accepted: 06 04 2021
entrez: 31 5 2021
pubmed: 1 6 2021
medline: 1 6 2021
Statut: epublish

Résumé

Myocardial ischemia/reperfusion (IR) injury represents a critical problem associated with interventional approaches for coronary reperfusion. Pharmacological cardioprotective interventions are advocated to ameliorate IR injury. Melatonin is an anti-inflammatory and antioxidant agent with a wide range of therapeutic properties that may contribute to its cardioprotective effects. No systematic review or meta-analysis has compared melatonin vs. placebo as a cardioprotective agent in humans. The present study, based on a systematic review and meta-analysis, was carried out to assess melatonin's efficacy as a cardioprotective treatment. We performed a systematic review of the available literature. Randomized controlled trials (RCTs) were identified and information was extracted using predefined data extraction forms. The primary outcomes were (a) left ventricular ejection fraction (LVEF) and (b) blood troponin levels in patients who underwent myocardial revascularization and were randomized to melatonin or placebo. The inverse-variance random-effects method was used to pool the estimates. Heterogeneity and publication bias were assessed. Weighted mean differences or standardized mean differences were calculated. A total of 283 records were screened and seven RCTs met all the inclusion criteria. After the pooled analysis, the results on LVEF were consistent across all studies, and a significant heterogeneity was found in the results on troponin levels. The melatonin-treated patients had on average higher LVEF than the placebo-treated individuals with a weighted mean difference = 3.1% (95% CI 0.6-5.5,

Identifiants

pubmed: 34055929
doi: 10.3389/fcvm.2021.635083
pmc: PMC8149621
doi:

Types de publication

Systematic Review

Langues

eng

Pagination

635083

Informations de copyright

Copyright © 2021 Domínguez-Rodríguez, Abreu-González, Báez-Ferrer, Reiter, Avanzas and Hernández-Vaquero.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Eur Heart J. 2020 Jan 1;41(1):12-85
pubmed: 31820000
Iran J Pharm Res. 2015 Summer;14(3):851-5
pubmed: 26330873
World J Cardiol. 2014 Mar 26;6(3):100-6
pubmed: 24669291
Front Physiol. 2018 May 17;9:528
pubmed: 29867569
J Biol Chem. 1960 Jul;235:1992-7
pubmed: 14415935
J Pineal Res. 2014 Aug;57(1):10-5
pubmed: 24708480
Nat Rev Cardiol. 2020 Dec;17(12):773-789
pubmed: 32620851
Expert Opin Investig Drugs. 2012 Nov;21(11):1593-6
pubmed: 22916801
Clin Pharmacokinet. 2016 Sep;55(9):1027-30
pubmed: 27000757
Front Physiol. 2020 Apr 29;11:366
pubmed: 32411013
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Int J Cardiol. 2016 Oct 15;221:977-86
pubmed: 27441478
J Cardiovasc Transl Res. 2017 Dec;10(5-6):470-479
pubmed: 29027116
Front Biosci (Landmark Ed). 2012 Jun 01;17:2433-41
pubmed: 22652790
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Oxid Med Cell Longev. 2013;2013:676829
pubmed: 23691266
Medicine (Baltimore). 2018 Jul;97(30):e11383
pubmed: 30045259
Circ Res. 2019 Jul 5;125(2):245-258
pubmed: 31268854
J Pineal Res. 2010 Aug;49(1):14-22
pubmed: 20536686
Physiology (Bethesda). 2020 Mar 1;35(2):86-95
pubmed: 32024428
J Am Coll Cardiol. 2019 Jan 8;73(1):89-99
pubmed: 30621955
Am J Cardiol. 2017 Aug 15;120(4):522-526
pubmed: 28645475
J Am Coll Cardiol. 2019 Jul 16;74(2):238-256
pubmed: 31296297
Atherosclerosis. 2008 Jul;199(1):73-8
pubmed: 18054940
Oxid Med Cell Longev. 2020 Jun 26;2020:1241065
pubmed: 32685084

Auteurs

Alberto Domínguez-Rodríguez (A)

Hospital Universitario de Canarias, Servicio de Cardiología, Tenerife, Spain.
Departamento de Enfermería, Facultad de Ciencias de la Salud, Universidad de La Laguna Tenerife, San Cristóbal de La Laguna, Spain.

Pedro Abreu-González (P)

Departamento de Fisiología, Facultad de Medicina, Universidad de La Laguna, Tenerife, San Cristóbal de La Laguna, Spain.

Néstor Báez-Ferrer (N)

Hospital Universitario de Canarias, Servicio de Cardiología, Tenerife, Spain.

Russel J Reiter (RJ)

Department of Cell Systems and Anatomy UT Health San Antonio, Long School of Medicine, San Antonio, TX, United States.

Pablo Avanzas (P)

Área del Corazón, Hospital Universitario Central de Asturias, Oviedo, Spain.
Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.

Daniel Hernández-Vaquero (D)

Área del Corazón, Hospital Universitario Central de Asturias, Oviedo, Spain.
Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.

Classifications MeSH